{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:42:19Z","timestamp":1772692939609,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objective: Very late relapses (VLRs) in Hodgkin lymphoma (HL), occurring \u22655 years after initial treatment, have been well-recognized for decades. Recent studies have highlighted the persistent and linear risk of relapse extending well beyond 5 years, while also describing the incidence and risk factors. However, extremely late relapses (EXLRs) occurring \u226520 years after diagnosis remain poorly described and largely limited to case reports. In the present study, we focus on patients experiencing EXLRs after chemotherapy or combined modality therapy, aiming to define their incidence, clinical characteristics, and outcomes, and to compare them with patients with VLRs relapsing between 5 and 20 years from initial diagnosis. Methods: We performed a retrospective study of 270 patients with HL, who received chemotherapy \u00b1 radiotherapy (CT \u00b1 RT), remained in continuous remission at least 5 years from treatment initiation and had follow-up data exceeding 20 years from diagnosis. The primary endpoint was the cumulative incidence (CumInc) of VLR, considering death from any cause as a competing event. Results: EXLR occurred in 9\/270 cases. The CumInc of EXLR at 25, 30 and 35.2 years was 2.23%, 4.80% and 7.87%, respectively. Compared to patients with VLRs (N = 61), patients with EXLRs had a lower incidence of anemia and a higher incidence of lymphocytopenia at diagnosis. At relapse, patients with EXLR tended to be older, had a lower frequency of extranodal disease, were more often managed with the same or similar salvage CT regimen as at initial diagnosis (reinduction), and were considered less frequently as candidates for autologous stem cell transplantation. In univariate analysis, the omission of RT at initial treatment and the histologic subtype of mixed cellularity (MC) were associated with a higher probability of EXLR. Compared to patients with VLRs, patients with EXLRs had a 10-year treatment to second failure (TT2F) of 88.9% versus 47.4%, a 10-year overall survival after relapse (O2S) of 77.8% versus 54.9% and a 10-year disease-specific survival (DSS) of 88.9% versus 70.9%. Conclusions: The study describes for the first time the incidence and characteristics of EXLRs in HL. These patients had excellent outcome despite having relapsing disease, suggesting that this subgroup of patients may have distinct biological characteristics.<\/jats:p>","DOI":"10.3390\/cancers18050777","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:18:45Z","timestamp":1772554725000},"page":"777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Focus on Extremely Late Relapses in Hodgkin Lymphoma: A Single Center Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Athanasios","family":"Liaskas","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Morrow Transplantation, \u201cLaikon\u201d General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-6142","authenticated-orcid":false,"given":"Fotios","family":"Panitsas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Morrow Transplantation, \u201cLaikon\u201d General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Morrow Transplantation, \u201cLaikon\u201d General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-4657","authenticated-orcid":false,"given":"Marina","family":"Siakantaris","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Morrow Transplantation, \u201cLaikon\u201d General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos A.","family":"Pangalis","sequence":"additional","affiliation":[{"name":"Athens Medical Center, \u201cPsychikon\u201d Branch, 11525 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Morrow Transplantation, \u201cLaikon\u201d General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mpo.2950120218","article-title":"Late recurrence in Hodgkin\u2019s disease: A report of two cases","volume":"12","author":"Green","year":"1984","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-102-3-292","article-title":"Late relapse among patients treated for Hodgkin\u2019s disease","volume":"102","author":"Herman","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0936-6555(05)80098-6","article-title":"Hodgkin\u2019s disease: A case of late relapse","volume":"5","author":"Lee","year":"1993","journal-title":"Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1200\/JCO.1993.11.2.225","article-title":"Late relapse in early-stage Hodgkin\u2019s disease patients enrolled on European Organization for Research and Treatment of Cancer protocols","volume":"11","author":"Bodis","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1422::AID-CNCR20>3.0.CO;2-0","article-title":"Late relapse after treatment for clinical stage I and II Hodgkin\u2019s disease","volume":"79","author":"Brierley","year":"1997","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<560::AID-CNCR26>3.0.CO;2-T","article-title":"Favorable prognosis after late relapse of Hodgkin\u2019s disease","volume":"83","author":"Arcediano","year":"1998","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000421-200112000-00009","article-title":"Very late relapse of Hodgkin\u2019s disease: A report of five patients","volume":"24","author":"Shihabi","year":"2001","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12032-007-9012-4","article-title":"Hodgkin\u2019s lymphoma relapse in the uterine cervix 15 years after the initial cure","volume":"25","author":"Mihaljevic","year":"2008","journal-title":"Med. Oncol."},{"key":"ref_9","first-page":"637","article-title":"Late relapse of Hodgkin\u2019s lymphoma presenting as fatal hematemesis caused by an esophago-tracheo-arterial fistula","volume":"11","author":"Kutchuk","year":"2009","journal-title":"Isr. Med Assoc. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3109\/10428194.2010.500432","article-title":"Late relapses in Hodgkin lymphoma: A clinical and immunohistochemistry study","volume":"51","author":"Provencio","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"707542","DOI":"10.1155\/2011\/707542","article-title":"Outcome of Very Late Relapse in Patients with Hodgkin\u2019s Lymphomas","volume":"2011","author":"Gaudio","year":"2011","journal-title":"Adv. Hematol."},{"key":"ref_12","first-page":"481","article-title":"Late relapse of Hodgkin\u2019s lymphoma\u2014Is it different in clinical characteristics and outcome?","volume":"22","author":"Markovic","year":"2017","journal-title":"JBUON"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.clml.2023.07.012","article-title":"Very late relapse in Hodgkin lymphoma: Characterizing an understudied population","volume":"23","author":"Cherniawsky","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/10428199709058350","article-title":"Very late relapse of Hodgkin\u2019s disease after 24 years of complete remission","volume":"28","author":"Dimopoulos","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1097-0142(19880101)61:1<186::AID-CNCR2820610131>3.0.CO;2-1","article-title":"Recurrence of Hodgkin\u2019s disease 29 years later","volume":"61","author":"Hung","year":"1988","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials","volume":"35","author":"Goergen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.18180","article-title":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma\u2014A study from the Danish Lymphoma Registry","volume":"198","author":"Andersen","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-022-00674-w","article-title":"Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: Linear pattern and distinct prognostic factors","volume":"12","author":"Vassilakopoulos","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_19","first-page":"14","article-title":"Very Late Relapses in Hodgkin Lymphoma: A Critical Comparison of Major Published Studies","volume":"13","author":"Liaskas","year":"2022","journal-title":"Haema"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Arapaki, M., Diamantopoulos, P.T., Liaskas, A., Panitsas, F., Siakantaris, M.P., Dimou, M., Kokoris, S.I., Sachanas, S., and Belia, M. (2024). Prognostic Impact of Serum \u03b22-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients. Cancers, 16.","DOI":"10.3390\/cancers16020238"},{"key":"ref_21","first-page":"141","article-title":"An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand. J. Stat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-10-1271","article-title":"Clonal relationship of classical hodgkin lymphoma and its recurrences","volume":"17","author":"Obermann","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41379-021-00983-8","article-title":"Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements","volume":"35","author":"Rijntjes","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Liaskas, A., Pereyra, P., Panayiotidis, P., Angelopoulou, M.K., and Gallamini, A. (2023). Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713187"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:28:13Z","timestamp":1772688493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050777"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050777","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}